1. Home
  2. Research
  3. Research Groups
  4. Translational Haematology

Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy

Search for publications

Only original articles, editorials, guidelines.

  • Rosiñol L, Hebraud B, Oriol A, Colin AL, Ríos Tamayo R, Hulin C, Blanchard MJ, Caillot D, Sureda A, Hernández MT, Arnulf B, Mateos MV, Macro M, San-Miguel J, Belhadj K, Lahuerta JJ, Garelik MB, Bladé J, Moreau P.

    Integrated analysis of randomized controlled trials evaluating bortezomib plus lenalidomide plus dexamethasone or bortezomib plus thalidomide plus dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

    Frontiers in Oncology . 13: 1197340-1197340.

    [doi:10.3389/fonc.2023.1197340]

  • Rosiñol L, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Hernandez Garcia MT, Cabañas V, Carrillo-Cruz E, Sureda A, Martinez-Lopez J, Krsnik I, Gonzalez ME, Casado Montero LF, Marti JM, Encinas C, de Arriba F, Palomera L, Sampol A, Gonzalez-Montes Y, Cabezudo E, Paiva B, Puig N, Cedena MT, de la Cruz J, Mateos MV, San-Miguel J, Lahuerta JJ, Bladé J.

    Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

    Blood . 142(18): 1518-1528. Number of citations: 1

    [doi:10.1182/blood.2022019531]

  • Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto LM, Guttke C, Gyan E, Hamad N, Herrera P, Hultberg A, Jacobs J, Johnson AJ, Langlois A, Ma X, Martinelli G, Arnan M, Müller R, Nottage K, Ofran Y, Özcan M, Samoilova O, Tolbert JA, Trudel GC, Xiu L, Vey N, Wei AH.

    Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

    LANCET HAEMATOLOGY . 10(11): 902-912. Number of citations: 1

    [doi:10.1016/S2352-3026(23)00207-7]

  • Rodríguez-Mora S, Corona M, Solera Sainero M, Mateos E, Torres M, Sánchez-Menéndez C, Casado-Fernández G, García-Pérez J, Pérez-Olmeda M, Murciano-Antón MA, López-Jiménez J, Coiras M, García-Gutiérrez V.

    Regular Humoral and Cellular Immune Responses in Individuals with Chronic Myeloid Leukemia Who Received a Full Vaccination Schedule against COVID-19

    Cancers . 15(20): .

    [doi:10.3390/cancers15205066]

  • Piñana JL, Heras I, Aiello TF, García-Cadenas I, Vazquez L, Lopez-Jimenez J, Chorão P, Aroca C, García-Vidal C, Arroyo I, Soler-Espejo E, López-Corral L, Avendaño-Pita A, Arrufat A, Garcia-Gutierrez V, Arellano E, Hernández-Medina L, González-Santillana C, Morell J, Hernández-Rivas JÁ, Rodriguez-Galvez P, Mico-Cerdá M, Guerreiro M, Campos D, Navarro D, Cedillo Á, Martino R, Solano C.

    Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    VIRUSES-BASEL . 15(10): .

    [doi:10.3390/v15102066]

  • Martín García-Sancho A, Rodríguez-Pinilla SM, Domingo-Domenech E, Climent F, Sánchez-Garcia J, López Jiménez J, García-Cosío Piqueras M, Castellvi J, González AJ, González de Villambrosia S, Gómez Codina J, Navarro B, Rodríguez G, Borrero JJ, Fraga M, Naves A, Baeza L, Córdoba R.

    Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study

    BRITISH JOURNAL OF HAEMATOLOGY . 203(2): 182-193.

    [doi:10.1111/bjh.18941]

  • Chumbita M, Puerta-Alcalde P, Yáñez L, Angeles Cuesta M, Chinea A, Español-Morales I, Fernandez-Abellán P, Gudiol C, González-Sierra P, Rojas R, Sánchez-Pina JM, Vadillo IS, Sánchez M, Varela R, Vázquez L, Guerreiro M, Monzo P, Lopera C, Aiello TF, Peyrony O, Soriano A, Garcia-Vidal C.

    High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations

    Microbiology spectrum . 11(4): . Number of citations: 1

    [doi:10.1128/spectrum.00674-23]

  • Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM.

    Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

    Haematologica . 109(2): 543-552. Number of citations: 1

    [doi:10.3324/haematol.2023.283342]

  • Norman FF, Gonzalez-Sanz M, Gullón-Peña B, Chamorro-Tojeiro S, Rosas M, Crespillo-Andujar C, Monge-Maillo B, Comeche B, Corbacho-Loarte MD, Arcas C, Peña I, Tenorio MC, Lopez-Vélez R, Pérez-Molina JA.

    Haemoglobinopathies in mobile populations from sub-Saharan Africa

    JOURNAL OF TRAVEL MEDICINE . : .

    [doi:10.1093/jtm/taad115]

  • Alvarez-Larrán A, Cuevas B, Velez P, Noya S, Caballero-Navarro G, Ferrer-Marín F, Carbonell S, Pérez-Encinas M, Gómez-Casares MT, Pérez-López R, Magro E, Moretó A, Pastor-Galán I, Angona A, Mata-Vázquez MI, Guerrero-Fernández L, Guerra JM, Carreño-Tarragona G, Fox L, Murillo I, García-Gutiérrez V, Mora E, Stuckey R, Arellano-Rodrigo E, Hernández-Boluda JC, Pereira A.

    Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia

    Hemasphere . 7(8): .

    [doi:10.1097/HS9.0000000000000936]

  • de la Asunción CS, Giménez E, Hernández-Boluda JC, Terol MJ, Albert E, López J, García-Gutiérrez V, Andreu R, Malo MDG, Fox ML, Remigia MJ, Amat P, Solano C, Navarro D.

    Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study

    JOURNAL OF MEDICAL VIROLOGY . 95(7): .

    [doi:10.1002/jmv.28933]

  • Berning P, Schmitz N, Ngoya M, Finel H, Boumendil A, Wang F, Huang XJ, Hermine O, Philippe L, Couronné L, Jaccard A, Liu D, Wu D, Reinhardt HC, Chalandon Y, Wagner-Drouet E, Kwon M, Zhang X, Carpenter B, Yakoub-Agha I, Wulf G, López-Jiménez J, Sanz J, Labussière-Wallet H, Shimoni A, Dreger P, Sureda A, Kim WS, Glass B.

    Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

    Leukemia . 37(7): 1511-1520. Number of citations: 1

    [doi:10.1038/s41375-023-01924-x]

  • de la Rubia J, Alonso R, Clavero ME, Askari E, García A, Antón C, Fernández M, Escalante F, García A, Rios-Tamayo R, Conesa V, Bermúdez MA, Merchán B, Velasco AE, Blanchard MJ, Sampol A, Gainza E, Hernández PM, Alegre A.

    Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain

    Cancers . 15(11): . Number of citations: 2

    [doi:10.3390/cancers15112964]

  • Martínez-Cuadrón D, Megías-Vericat JE, Gil C, Bernal T, Tormo M, Martínez-Sánchez P, Rodríguez-Medina C, Serrano J, Herrera P, Simón JAP, Sayas MJ, Bergua J, Lavilla-Rubira E, Amigo ML, Benavente C, Lorenzo JLL, Pérez-Encinas MM, Vidriales MB, Colorado M, De Rueda B, García-Boyero R, Marini S, García-Suárez J, López-Pavía M, Gómez-Roncero MI, Noriega V, López A, Labrador J, Cabello A, Sossa C, Algarra L, Stevenazzi M, Solana-Altabella A, Boluda B, Montesinos P.

    Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.

    Haematologica . 109(1): 115-128. Number of citations: 1

    [doi:10.3324/haematol.2022.282506]

  • Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E, Bilbao C, Prados de la Torre E, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua J, Algarra L, Tormo M, Martínez-Sánchez P, Soria E, Serrano J, Alonso-Dominguez JM, García R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez Casares MT, Sánchez-García J, Barragán E, Montesinos P.

    Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

    BLOOD CANCER JOURNAL . 13(1): 77-77. Number of citations: 1

    [doi:10.1038/s41408-023-00835-5]

  • Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH.

    Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE

    BRITISH JOURNAL OF HAEMATOLOGY . : . Number of citations: 1

    [doi:10.1111/bjh.18883]

  • Ayala R, Fernández RA, García-Gutiérrez V, Alvarez-Larrán A, Osorio S, Sánchez-Pina JM, Carreño-Tarragona G, Álvarez N, Gómez-Casares MT, Duran A, Gorrochategi J, Hernández-Boluda JC, Martínez-López J.

    Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.

    Ejhaem . 4(2): 401-409.

    [doi:10.1002/jha2.685]

  • Piñana JL, Martino R, Vazquez L, López-Corral L, Pérez A, Chorão P, Avendaño-Pita A, Pascual MJ, Sánchez-Salinas A, Sanz-Linares G, Olave MT, Arroyo I, Tormo M, Villalon L, Conesa-Garcia V, Gago B, Terol MJ, Villalba M, Garcia-Gutierrez V, Cabero A, Hernández-Rivas JÁ, Ferrer E, García-Cadenas I, Teruel A, Navarro D, Cedillo Á, Sureda A, Solano C.

    SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

    BONE MARROW TRANSPLANTATION . 58(5): 567-580. Number of citations: 10

    [doi:10.1038/s41409-023-01946-0]